Preclinical testing of 3 cysteine-related drugs for reducing dystropathology in the mdx mouse model of Duchenne Muscular Dystrophy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1065829

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Duchenne muscular dystrophy (DMD) is devastating disease that affects young boys. We propose testing 3 cysteine related drugs which show promise in ameliorating the severity of the disease. The drugs are of particular interest because they are relatively inexpensive, can be taken orally, have few side effects and are already approved for human use. These drugs will tested in an animal model of DMD to test their efficacy.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $378,564.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Systems Physiology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug efficacy | mouse models | muscle pathologies | muscular dystrophy | physiology

Related Links